AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03955887 — intervention group
Intervention type: BIOLOGICAL
Intervention: bronchoalveolar lavage fluid (BAL)
Description: Recovery of a 10 mL volume of BAL fluid, performed as part of patient care
Study NCT03955887 — intervention group
Intervention type: BIOLOGICAL
Intervention: Venous blood
Description: Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care
Study NCT02979886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH-a
Description: the hormone reaction to the down regulation of the patients
Study NCT02979886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Menopausal Gonadotropins
Description: the effects on the serum LH level of day of HCG
Study NCT02665234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Tavilermide Ophthalmic Solution
Description: 1% Tavilermide BID Dosing
Study NCT02665234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Vehicle Ophthalmic Solution
Study NCT03374514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: instilation of the solution in the middle ear
Study NCT03374514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile isotonic saline solution
Description: Sterile isotonic saline solution
Study NCT03535324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROA for optimization
Description: The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.
Study NCT03535324 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: There will be no intervention
Study NCT01596920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue
Description: Allograft Tissue Cellular Repair Matrix
Study NCT01596920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non-adherent Dressing
Study NCT01993550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Study NCT01993550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study NCT02647502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
Study NCT02647502 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
Study NCT02647502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
Study NCT02852915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: Laparoscopic surgery for T4 cancer
Study NCT02167776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Church-based teaching
Description: In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
Study NCT01302886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHQ880
Study NCT02424162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: +2.75 diopters multifocal intraocular lens
Study NCT02424162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: +3.25 diopters multifocal intraocular lens
Study NCT00388609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-646256
Description: Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
Study NCT00388609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
Study NCT05099315 — intervention group
Intervention type: OTHER
Intervention: not applicable, observational study
Description: Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
Study NCT02534922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prolanta, a human prolactin receptor antagonist
Description: Daily subcutaneous dosing
Study NCT04868422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring via wireless internet-based system
Study NCT02552225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
Study NCT02552225 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
Study NCT01085903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg once daily with morning meal for three days administered only to stroke patients
Study NCT01085903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
Study NCT01085903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline
Description: Observations made at baseline before any intervention
Study NCT03616626 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Twice Daily APBI
Description: Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
Study NCT03616626 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Irradiation
Description: Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
Study NCT01634009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy-based RUTF (in double blind design)
Description: Soy-based RUTF will be given in double blind manner
Study NCT01712087 — intervention group
Intervention type: DEVICE
Intervention: MedStream Programmable Infusion System
Description: Intrathecal Infusion of Baclofen in the Treatment of Spasticity
Study NCT03515434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP Block
Description: ESP block will be performed at the finishing of surgery under spinal anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 2-3 cm lateral to T10 spinous process. The erector spinae muscles will be identified superficial to the tip of T10 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
Study NCT03515434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: TAP block will be performed at the finishing of surgery under spinal anesthesia. A linear ultrasound transducer will be placed to lateral aspect of abdomen. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane between transversus abdominis and internal oblique muscles..A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
Study NCT02960139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test- Treatment with Sylys Surgical Sealan
Description: Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
Study NCT03515434 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT03515434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT01085903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPS
Description: Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
Study NCT04058119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body therapies
Description: Sessions of body-mind therapies (yoga, qigong and pilates), oriented by certified instructors. Every sessions will be 60-minutes long, biweekly, with a total duration of 6 months.
Study NCT03740607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Healthcare virtual reality software implemented during peripheral intravenous catheter placement
Study NCT03740607 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral intravenous catheter placement
Description: Peripheral intravenous catheters are placed in the peri-operative suites in preparation for anesthesia during surgery.
Study NCT03740607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous catheter placement
Description: Peripheral intravenous catheters are placed in the peri-operative suites in preparation for anesthesia during surgery.
Study NCT01085903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Post CPS
Description: 20 minutes following the CPS condition.
Study NCT00551720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
Study NCT00551720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement
Description: Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
Study NCT02044159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
Study NCT02044159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
Study NCT00243230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc 30 mg
Description: Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).
Study NCT00243230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc 20 mg
Description: Two tablets of vicriviroc 10 mg once daily for 48 weeks.
Study NCT00243230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three tablets of placebo once daily for 48 weeks.
Study NCT00243230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two tablets of placebo once daily for 48 weeks.
Study NCT00243230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background ART Regimen
Description: An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir.
Study NCT00243230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background ART Regimen
Description: An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir.
Study NCT02467803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapula mobilization
Study NCT02467803 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder ROM exercises
Study NCT02467803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder ROM exercises
Study NCT01085903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow up
Description: Follow up testing occurred at 3 months
Study NCT03622606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Right Language screening test (R-LAST)
Description: Validation of the Right Language screening test in acute and subacute phase of right stroke
Study NCT01137084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solu medrol
Description: total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
Study NCT01137084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: a steroid-free immunosuppression protocol
Description: receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
Study NCT00808873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: socio-educational intervention
Description: brief mental health education and 6 follow-up visits
Study NCT02269111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo DW-MRI
Study NCT01329133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation (DBS)
Description: In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
Study NCT02485886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BMV101
Description: 68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
Study NCT02269111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemical exchange saturation transfer magnetic resonance imaging
Description: Undergo CEST-MRI
Study NCT02269111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI
Study NCT02269111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic susceptibility contrast-enhanced magnetic resonance imaging
Description: Undergo DSC-MRI
Study NCT01539031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020
Description: Subjects in the Group-10 mg:~Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg
Study NCT03200457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1,5 Tesla abdominal MRI
Description: Measurement of the fat and iron
Study NCT03200457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 Tesla abdominal MRI
Description: Measurement of the fat and iron
Study NCT03153215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment
Description: We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.
Study NCT03153215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.
Study NCT02679248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neo40 Daily®
Study NCT02679248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00038701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-470
Study NCT00152815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antioxidant vitamin E
Description: Vitamin E 800IU per day for 12 months
Study NCT00152815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight reduction and exercise
Description: Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
Study NCT01675531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targin
Description: Single arm for Targin
Study NCT01539031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2020
Description: Subjects in the Group-23 mg:~Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg
Study NCT04505800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tryptophan supplement
Description: * Pure L-tryptophan in capsules (500mg/capsule)~* 3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)
Study NCT04505800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltose
Description: Maltose
Study NCT02662751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Imaging Assessment
Description: Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers.
Study NCT02662751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Imaging Assessment
Description: Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers.
Study NCT02662751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LDWBA first (CT scan)
Description: Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient.
Study NCT02383784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low GI index diet
Description: Low glycemic index diet